Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 38 of 52 for:    cataract AND ophthalmic suspension

Dropless vs. Standard Drops Contralateral Eye Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02515045
Recruitment Status : Completed
First Posted : August 4, 2015
Results First Posted : August 22, 2017
Last Update Posted : February 23, 2018
Sponsor:
Collaborator:
Science in Vision
Information provided by (Responsible Party):
Carolina Eyecare Physicians, LLC

Brief Summary:
To compare the use of an injectable compound containing an antibiotic and an anti-inflammatory at time of cataract surgery to standard of care that is the use 3 different topical medications to prevent inflammation and infection after routine cataract surgery.

Condition or disease Intervention/treatment Phase
Cataract Drug: TriMoxiVanc Drug: Moxifloxacin HCl 0.5% Drug: Ilevro Drug: Prednisolone acetate 1% Phase 4

Detailed Description:

Key factors for a successful cataract surgery include, among others, preoperative measurements for accurate intraocular lens (IOL) calculation, surgical technique and surgeon's experience but also the use of prophylactic topical antibiotics and anti-inflammatories (steroidal and non-steroidal, NSAID) to decrease the risk of postoperative infection (i.e. endophthalmitis) and intraocular inflammation (i.e. macular edema, CME).

Even though, the large body of literature that supports the significance of prophylactic eye drops prior to surgery, patient compliance is a common problem. Different factors have been associated with patient's lack of compliance. It could be due to patient's inability to self administer the drops, lack of understanding of the importance of using the prophylactic treatment as well as understanding the instructions of how to administer the drops and its storage, or just forgetfulness or the fact that they don't like to put the drops multiple times a day for 2-4 weeks, therefore they just avoid doing it.

There is a new option called "Dropless cataract surgery". This modality of treatment involves the injection of an eye compatible compound at time of cataract surgery.

The purpose of is to assess the efficacy the compound injected during routine cataract surgery and intraocular (IOL) implantation with and without a topical NSAID compared to standard prophylactic treatment that includes the topical use of Moxifloxacin, Ilevro, and Prednisolone acetate 1%.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 59 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Comparison of Dropless Prophylaxis After Routine Phacoemulsification to Standard Drops Regimen
Study Start Date : January 2015
Actual Primary Completion Date : March 2016
Actual Study Completion Date : March 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cataract

Arm Intervention/treatment
Active Comparator: TriMoxiVanc
The formulation containing triamcinolone acetonide, moxifloxacin hydrochloride and vancomycin used as an injection at the end of the uneventful phacoemulsification procedure. The compounded Tri-Moxy-Vanco will be delivered into the vitreous cavity using a transzonular approach after IOL implantation before removal of the OVD.
Drug: TriMoxiVanc
triamcinolone acetonide 15 mg / ml with moxifloxacin 1 mg/ml, vancomycin 10 mg/ml to be injected at time of cataract surgery.
Other Name: Dropless

Active Comparator: TriMoxiVanc + Ilevro
Nepafenac ophthalmic suspension 0.3% will be started 3 days prior to surgery QD and continue QD for 4 weeks after surgery. The compounded Tri-Moxy-Vanco will be injected into the vitreous cavity using a transzonular approach after IOL implantation before removal of the OVD.
Drug: TriMoxiVanc
triamcinolone acetonide 15 mg / ml with moxifloxacin 1 mg/ml, vancomycin 10 mg/ml to be injected at time of cataract surgery.
Other Name: Dropless

Drug: Ilevro
NSAID to be used 1 drop QD starting 3 days before surgery and QD for 4 weeks after surgery.
Other Name: Nepafenac 0.3%

Active Comparator: Control

Moxifloxacin HCl 0.1%, 1 drop, QID for 3 days prior to surgery and will continue for 2 weeks after surgery and then discontinue.

Nepafenac ophthalmic suspension 0.3% : 1 drop QD starting 3 days before surgery and QD for 4 weeks after surgery.

Prednisolone acetate 1% will be started after surgery QID for 2 weeks, tapered to BID for 2 weeks, and then discontinued.

Drug: Moxifloxacin HCl 0.5%
Antibiotic to be used 1 drop, QID for 3 days prior to surgery and will continue for 2 weeks after surgery and then discontinue.
Other Name: Vigamox, Moxeza

Drug: Ilevro
NSAID to be used 1 drop QD starting 3 days before surgery and QD for 4 weeks after surgery.
Other Name: Nepafenac 0.3%

Drug: Prednisolone acetate 1%
Steroid to be started after surgery 1 drop QID for 2 weeks, tapered to BID for 2 weeks, and then discontinued.
Other Name: Pred Forte, Econopred Plus, Omnipred




Primary Outcome Measures :
  1. Change From Baseline (Preoperative Exam) in Macular Thickness [ Time Frame: Month 1. ]
    Macula is the area in the retina that is responsible for the best central vision. Changes in its thickness may occur after cataract surgery due to the normal inflammatory process that occurs postoperatively but it returns to preoperative values unless there is an underlying disease.


Secondary Outcome Measures :
  1. Change From Baseline (Preoperative Exam) in Pachymetry (Corneal Thickness) [ Time Frame: Month 1 ]

    Cornea is the clear part of the front of the eye. Normal corneal thickness is in average 0.540 mm. The corneal thickness is measured with a handheld device called pachymeter.

    An increase in corneal thickness may indicate corneal edema (swelling of the cornea) that could be seen after ocular surgery.


  2. Change From Baseline (Preoperative Exam) in Intraocular Pressure (IOP) [ Time Frame: Month 1. ]
    Intraocular pressure refers to the pressure inside the eye. It is measured in mmHg using a device called a tonometer. The mean IOP is 15.5 mmHg. Raised IOP after cataract surgery is common and in most cases it is transient and benign.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject is undergoing bilateral cataract extraction or refractive lens exchange with intraocular lens implantation.
  • Willing and able to provide written informed consent for participation in the study.
  • Willing and able to comply with scheduled visits and other study procedures.
  • Willing and able to administer eye drops and record the times the drops were instilled.
  • Scheduled to undergo standard cataract surgery with topical anesthesia in both eyes within 6-15 days between surgeries.
  • Potential postoperative best-corrected visual acuity of 20/30 or better

Exclusion Criteria:

  • Severe preoperative ocular pathology: amblyopia, rubella cataract, proliferative diabetic retinopathy, shallow anterior chamber, macular edema, aniridia or iris atrophy, uveitis, history of iritis, iris neovascularization, medically uncontrolled glaucoma, microphthalmos or macrophthalmos, optic nerve atrophy, macular degeneration (with anticipated best postoperative visual acuity less than 20/30), advanced glaucomatous damage, etc.
  • Presence of epiretinal membrane.
  • Uncontrolled diabetes.
  • Use of any systemic or topical drug known to interfere with visual performance.
  • Contact lens use during the active treatment portion of the trial.
  • Any concurrent infectious/non infectious conjunctivitis, keratitis or uveitis.
  • History of chronic intraocular inflammation.
  • History of retinal detachment.
  • Pseudoexfoliation syndrome or any other condition that has the potential to weaken the zonules.
  • Previous radial keratotomy.
  • Any additional ocular surgical procedures at time of cataract extraction (i.e. iStent) except corneal incisions for the correction of astigmatism.
  • Anesthesia other than topical anesthesia (i.e. retrobulbar, general, etc).
  • Any clinically significant, serious or severe medical or psychiatric condition that may increase the risk associated with study participation or may interfere with the interpretation of study results.
  • Participation in (or current participation) any investigational drug or device trial within the previous 30 days prior to the start date of this trial.
  • Intraocular conventional surgery within the past three months or intraocular laser surgery within one month.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02515045


Locations
Layout table for location information
United States, Minnesota
Minnesota Eye Consultants, P.A.
Bloomington, Minnesota, United States, 55431
Associated Eye Care
Stillwater, Minnesota, United States, 55082
United States, New York
Ophthalmic Consultants of Long Island
Garden City, New York, United States, 11530
United States, South Carolina
Carolina Eyecare Physicians, LLC
Mount Pleasant, South Carolina, United States, 29464
Sponsors and Collaborators
Carolina Eyecare Physicians, LLC
Science in Vision
Investigators
Layout table for investigator information
Principal Investigator: Kerry D Solomon, MD Carolina Eyecare Physicians, LLC

Layout table for additonal information
Responsible Party: Carolina Eyecare Physicians, LLC
ClinicalTrials.gov Identifier: NCT02515045     History of Changes
Other Study ID Numbers: CEP 14-002
First Posted: August 4, 2015    Key Record Dates
Results First Posted: August 22, 2017
Last Update Posted: February 23, 2018
Last Verified: January 2018

Keywords provided by Carolina Eyecare Physicians, LLC:
Cataract
Surgery
Prophylaxis

Additional relevant MeSH terms:
Layout table for MeSH terms
Cataract
Eye Diseases
Lens Diseases
Prednisolone
Methylprednisolone Acetate
Methylprednisolone
Methylprednisolone Hemisuccinate
Prednisolone acetate
Triamcinolone Acetonide
Nepafenac
Prednisolone hemisuccinate
Prednisolone phosphate
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents
Neuroprotective Agents
Protective Agents
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors